key: cord-0700270-nu0bx8r4
authors: Karakaş Çelik, Sevim; Çakmak Genç, Güneş; Pişkin, Nihal; Açikgöz, Bilgehan; Altinsoy, Bülent; Kurucu İşsiz, Başak; Dursun, Ahmet
title: Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID‐19: A case study
date: 2021-07-10
journal: J Med Virol
DOI: 10.1002/jmv.27160
sha: 5b6e9aeb7ab95bcf1683e4e33f3a644a2eb9307b
doc_id: 700270
cord_uid: nu0bx8r4

Coronavirus disease 2019 (COVID‐19) is an infectious disease, and the reason behind the currently ongoing pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Angiotensin‐converting enzyme (ACE2) has been recognized as the specific receptor of the SARS‐CoV‐2 virus. Although the possible effect of ACE2 gene polymorphism remains unknown, human ACE2 receptor expression influences SARS‐CoV‐2 susceptibility and COVID‐19 disease outcome. In this study, we aimed to investigate the relationship between ACE gene I/D polymorphism, ACE2 receptor gene polymorphism, and COVID‐19 severity. ACE gene insertion/deletion (I/D) polymorphism and ACE2 receptor gene rs2106809 and rs2285666 polymorphisms were determined using polymerase chain reaction (PCR) and PCR‐based restriction fragment length polymorphism methods, respectively, in 155 COVID‐19 patients who were divided into three groups (mild, moderate, and severe) according to clinical symptoms. However, the distribution of genotype and allele frequencies of ACE gene I/D, ACE2 receptor gene rs2106809, and rs2285666 polymorphisms were not statistically significant in all groups. In conclusion, in the study population, ACE gene I/D, ACE2 receptor gene rs2106809, and rs2285666 polymorphisms were not associated with the severity of COVID‐19 infection. Although ACE2 receptor gene expression may affect the susceptibility to COVID‐19, there is no existing evidence that the ACE or ACE2 gene polymorphisms are directly associated with COVID‐19 severity. Interindividual differences in COVID‐19 severity might be related to epigenetic mechanisms of ACE2 receptor gene expression or variations in other genes suggested to play a critical role in COVID‐19 pathogenesis such as pro‐inflammatory cytokines and coagulation indicators.

The entry of SARS-CoV-2, the agent that causes COVID-19, into the cell occurs by binding viral spike proteins to angiotensin-converting enzyme 2 (ACE2) receptors of the host membrane. It was suggested that increased susceptibility to COVID-19 infection is associated with the expression of the target ACE2 receptor in the epithelium exposed to the virus. 3 Low infection and complication level is present among children.

Serum ACE levels in children are higher than in adults and ACE2 receptor gene expression in the nasal epithelium, which is the first point of contact for SARS-CoV-2, was age-dependent, lowest in younger children, and increasing with age into adulthood. 4 It was also suggested that the lower risk among children is due to the lower expression of the ACE2 receptor. 5 Epidemiological data show that a majority of pediatric COVID-19 cases showed mild to moderate clinical features, and only a few developed severe or critical diseases (0.6% and 0.3%, respectively). 6 Of a total of 44 672 cases, only 1% is under 10 years old and in China. 7 Also, there is lower ACE2 receptor expression in children, highlighting the importance of ACE and ACE2 receptor expression level in COVID-19 severity.

A counter-regulatory relationship between ACE2 and ACE located on opposite axes in the renin-angiotensin system (RAS) has been reported. ACE plays an important role in converting angiotensin I to angiotensin II and ACE2 is a negative regulator of the RAS and counterbalances the function of ACE. The lungs are the primary organs for ACE receptor expression and generating circulating angiotensin II.

RAS plays a role in the pathogenesis of pulmonary hypertension and fibrosis, which are common chronic lung diseases. Recent studies show that RAS also plays an important role in acute lung diseases, particularly acute respiratory distress syndrome (ARDS). 8 A common 287 base pair insertion/deletion (I/D) polymorphism has been reported in intron 16 of the ACE gene and is known to be associated with serum levels of circulating ACE. Serum ACE concentrations were reported to be significantly higher in subjects with the D/D genotype compared to the I/D and I/I genotypes. 9 Considering the opposite effect between ACE and ACE2, decreased ACE2 receptor gene expression is strongly related to an increase in ACE expression. So it could be hypothesized that having a D allele for ACE I/D polymorphism affects the clinical course of the COVID-19 by decreasing the ACE2 receptor level.

Besides this, it has been shown that patients with chronic obstructive pulmonary disease (COPD) have increased gene expression of ACE2 receptor in bronchial epithelial cells in the lower respiratory tract, and also smoking has been shown to increase both the expression and activity of ACE2 in the airways. Although upregulation of ACE2 is beneficial in protecting the host against acute lung injury, this makes individuals more susceptible to coronavirus infections that use this receptor to enter epithelial cells. 10, 11 In the changes in the ACE2 receptor gene expression level, genetic variations play a very important role as well as environmental factors. Of the many polymorphisms identified in the ACE2 receptor gene, rs2106809 and rs2285666 are particularly remarkable. A bioinformatics tool called Human Splicing Finder (HSF) (v.3.0) predicts that the rs2106809 polymorphism, intronic single-nucleotide polymorphism (SNP) found in the ACE2 receptor gene, might create an intronic-exonic splicing enhancer site (ESE). It was suggested that the splicing efficiency of the ACE2 receptor gene may be influenced by the creation of these enhancer motifs. 12 It was also found that ACE2 rs2106809 CC or CT genotype carriers had higher circulating ACE2 receptor levels compared with TT genotype carriers. 13 The G8790A (rs2285666) polymorphism is at the fourth base of the third intron and situated in the intron adjoined to the exon, suggesting, this locus could alter messenger RNA (mRNA) alternate splicing and affect ACE2 receptor gene expression. It has also been reported that this polymorphism shows a strong linkage disequilibrium with the other SNPs Table 1 . COVID-19 severity is classified as follows;

Mild type: Outpatients, the clinical symptoms are mild, with no abnormal radiological findings, Moderate type: Hospitalized for persistent fever or pneumonia or mild respiratory distress or present pneumonia on chest computed tomography, Severe type: The disease is classified as severe if one of the following conditions is met:

1. Respiratory distress, respiratory rate ≥ 30/min.

2. Oxygen saturation on room air at rest ≤ 93%.

3. The partial pressure of oxygen in arterial blood/FiO 2 ≤ 300 mm Hg.

5. Another organ dysfunction is present, requiring intensive care unit monitoring and treatment. All digestion products were electrophoresed on 3% agarose gel and visualized by staining with ethidium bromide and evaluated using the gel documentation system (Syngene, Genegenius Bio Imaging System).

Genotype and allele frequency of the polymorphism was calculated in cases according to the severity of COVID-19. The χ 2 test was used to compare the genotype frequency of the ACE and ACE2 receptor gene polymorphisms in patients who have mild, moderate, or severe clinical symptoms. As the ACE2 receptor gene is located on the X chromosome and as males are hemizygous for ACE2, males and females were analyzed separately. A p value less than 0.05 was considered statistically significant. The software used for the calculations was SPSS version 18 (SPSS Inc.).

The present study included 155 patients with COVID-19, of which 78 were in the mild, 42 were in the moderate and 35 were in the severe group. Seventy-seven subjects were women spectively. The severity of the disease increased with age (p < 0.001). Also, it was found that gender differences affect COVID-19 severity and men tended to be affected more seriously than women (p = 0.003). The percentage of males was 60% in the severe groups and 40% for females. The clinical signs and symptoms of the patients with COVID-19 are given in Table 1 .

The distribution of each genotype for ACE I/D, ACE2 rs2106809, and rs2285666 in the COVID-19 patients according to the severity of the disease are shown in Table 2 . There was no statistically significant association between groups according to genotype (p = 0.191) and allele frequencies (p = 0.392) for ACE I/D gene polymorphism.

As ACE2 is on the X chromosome, data for each sex were analyzed separately in Tables 2. It was also found that the distribution of genotype and allele frequencies of ACE2 rs2106809 and rs2285666 gene polymorphisms were similar in all groups according to the severity of disease for both genders (p > 0.05).

Haplotype frequency and association analysis were also performed (Table 3) . We identified one haplotype for two polymorphisms (rs2106809 and rs2285666) in the ACE2 receptor gene. However, no statistical difference was noted (p = 0.519).

rs2106809 and rs2285666 polymorphisms were analyzed according to clinical symptoms and no significant relationship was found.

ACE2 has been established as the functional host receptor for SARS-CoV-2, responsible for the current devastating worldwide pandemic of COVID-19. 16 COVID-19 displays symptoms ranging from a mild cold to cardio-respiratory failure that may lead to death. 17 populations' data. It was suggested that there is a converse association between ACE D allele frequency and prevalence of COVID-19. Considering that the D allele frequency is lower in Asian populations than in European populations, the mortality rate and prevalence of COVID-19 in the Asia population is expected to be higher. However, the prevalence and mortality of COVID-19 in Europe are higher than in Asia. 19, 20 In contrast to Delangheet al., 19 Pati et al. 21 reported. 30 Besides this, the patients from the severe group showed elevated levels of inflammatory cytokines (such as IL-2, IL-2R, RIL-6, IL-8, and IL-10) and significant enhancement in coagulation parameters (such as D-dimer, prothrombin time, and fibrinogen), and increases in myocardial injury indicators. Therefore, inflammatory release, coagulation dysfunction, and myocardial injury correlate with disease severity and rise throughout the course of the disease. 31, 32 Thus, the severity of COVID-19 may be related to variations in genes encoding proinflammatory cytokines or other genes that are suggested to be associated with the occurrence of severe COVID-19.

In conclusion, our study does not support the hypothesis that 

The authors declare that there are no conflict of interests. 

Coronaviruses post-SARS: update on replication and pathogenesis

Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS

Serum angiotensinconverting enzyme activity in normal children and in those with sarcoidosis

Nasal gene expression of angiotensinconverting enzyme 2 in children and adults

Epidemiological and clinical features of pediatric COVID-19

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and prevention

Angiotensin-converting enzyme 2 in lung diseases

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19

Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract

Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites

Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients

The physiological significance of the alternative pathways of angiotensin II production

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical characteristics of coronavirus disease 2019 in China

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

The host's angiotensinconverting enzyme polymorphism may explain epidemiological findings in COVID-19 infections

No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection

ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: an epidemiological study in the Asian population

Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: an ecological metaregression

Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients

Angiotensinconverting enzymes (ACE, ACE2) gene variants and COVID-19 outcome

EZH2-mediated H3K27me3 inhibits ACE2 expression

Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain

ACE2 in the era of SARS-CoV-2: controversies and novel perspectives

Kinetics of viral load and antibody response in relation to COVID-19 severity

Viral dynamics in mild and severe cases of COVID-19

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study